Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Belantamab mafodotin

Phase 3

PPETHEMA Foundation

Belantamab mafodotin is one of 33 therapeutic programs targeting Multiple Myeloma. It is currently in Phase 3.

2

Indications

9

Total Trials

9

Active Trials

32

Competitors

Pipeline

Status by Indication[2][1]

Indication

Multiple MyelomaActive, not recruiting

Recurrent Multiple MyelomaRecruiting

Multiple MyelomaPhase 3

Active, not recruiting

Recurrent Multiple MyelomaPreclinical

Recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belantamab mafodotin

PPETHEMA Foundation

Ninlaro

Prolia

Eliquis

Bristol-Myers Squibb

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Adriamycin

GGynecologic Oncology Group

Nolvadex

Oncovin

EEastern Cooperative Oncology Group

Intron a

Systemic Therapy

Bristol-Myers Squibb

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Multiple Myeloma

NCT04162210

Phase 1Active, not recruiting

Multiple Myeloma

NCT04398745

PreclinicalActive, not recruiting

Multiple Myeloma

NCT07150104

PreclinicalActive, not recruiting

Multiple Myeloma

NCT07217119

PreclinicalActive, not recruiting

Multiple Myeloma

NCT07217184

Q4 2027

Not yet recruiting

Relapse Multiple Myeloma

NCT07637526

Clinical

Trials by Indication[1]

Multiple Myeloma7 trials

A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Clinical Activity of Belantamab as Monotherapy and in Combination With Other Treatments in Participants With Multiple Myeloma

Recruiting· GSK logo

GSK·Preclinical·NCT05714839·123 enrolled

A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Active, not recruiting· GSK logo

GSK·Phase 3·NCT04162210·325 enrolled

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04398745·36 enrolled

Show 4 more trials

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 7 - Belantamab Mafodotin, Nirogacestat, Pomalidomide, and Dexamethasone in Combination

Active, not recruiting· GSK logo

GSK·Preclinical·NCT07150104·14 enrolled

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination

Active, not recruiting· GSK logo

GSK·Preclinical·NCT07217119·25 enrolled

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5- Sub-study 5 - Belantamab Mafodotin and Isatuximab in Combination

Active, not recruiting· GSK logo

GSK·Preclinical·NCT07217184·30 enrolled

A Phase 2, Multicenter, Randomized, Open-label Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Alternative and Approved Dosing Regimens of Belantamab Mafodotin in Combination With Bortezomib and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

Not yet recruiting· GSK logo

GSK·Phase 2·NCT07614360·150 enrolled

Recurrent Multiple Myeloma1 trial

A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination With Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma

Recruiting·AAlliance for Clinical Trials in Oncology·Preclinical·NCT06232044·88 enrolled

Relapse Multiple Myeloma1 trial

Retrospective Observational Study to Evaluate the Effectiveness and Safety of Belantamab Mafodotin-based Combinations (Belantamab Mafodotin, Bortezomib, Dexamethasone [BVd] or Belantamab Mafodotin, Pomalidomide, Dexamethasone [BPd]) Used as Compassionate Use in Patients With Multiple Myeloma in First or Second Relapse

Not yet recruiting·PPETHEMA Foundation··NCT07637526·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Belantamab mafodotin. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Belantamab mafodotin. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — PETHEMA Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: PPETHEMA Foundation

Related News